Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04760288 |
| Title | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC) |
| Acronym | AcceleRET-MTC |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Hoffmann-La Roche |
| Indications | |
| Therapies | |
| Age Groups: | adult | child | senior |
| Covered Countries | ESP |
CKB BOOST